 | Up a level |
Hamzic, Seid; Amstutz, Ursula; Largiadèr, Carlo Rodolfo (2018). Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy? Pharmacogenomics, 19(8), pp. 689-692. Future Medicine 10.2217/pgs-2018-0040
Kummer, Dominic; Fröhlich, Tanja; Joerger, Markus; Aebi, Stefan; Sistonen, Johanna; Amstutz, Ursula; Largiadèr, Carlo Rodolfo (2015). Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics, 16(12), pp. 1367-1377. Future Medicine 10.2217/pgs.15.81
Visscher, Henk; Rassekh, S Rod; Sandor, George S; Caron, Huib N; van Dalen, Elvira C; Kremer, Leontien C; van der Pal, Helena J; Rogers, Paul C; Rieder, Michael J; Carleton, Bruce C; Hayden, Michael R; Ross, Colin J; Amstutz, Ursula; Canadian Pharmacogenomics Network for Drug Safety consortium, CPNDS (2015). Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics, 16(10), pp. 1065-1076. Future Medicine 10.2217/pgs.15.61
Sistonen, Johanna; Büchel, Barbara; Fröhlich, Tanja; Kummer, Dominic; Fontana, Stefano; Joerger, Markus; van Kuilenburg, André B P; Largiadèr, Carlo Rodolfo (2014). Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics, 15(13), pp. 1653-1666. Future Medicine 10.2217/pgs.14.126
Amstutz, Ursula; Froehlich, Tanja K; Largiadèr, Carlo R (2011). Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics, 12(9), pp. 1321-36. London: Future Medicine 10.2217/PGS.11.72
Becquemont, Ana; Amstutz, Ursula; Brauch, Hiltrud; Jacqz-Aigrain, Evelyne; Laurent-Puig, Pierre; A Molina, Miguel; Niemi, Mikko; Schwab, Matthias; A Somogyi, Andrew; Thervet, Eric; Maitland-van der Zee, Anke-Hilse; van Kuilenburg, André; van Schalk, Ron; Verstuyft, Céline; Wadelius, Mia; K Daly, Ann (2011). Practical recommendations for pharmacogenomics - based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics, 12(1), pp. 113-124. London: Future Medicine 10.2217/pgs.10.147
Stamer, Ulrike M; Zhang, Lan; Stüber, Frank (2010). Personalized therapy in pain management: where do we stand? Pharmacogenomics, 11(6), pp. 843-64. London: Future Medicine 10.2217/PGS.10.47
Amstutz, U; Farese, S; Aebi, S; Largiadèr, CR (2009). Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment. Pharmacogenomics, 10(6), pp. 931-944. London: Future Medicine 10.2217/PGS.09.28
Rauch, Andri; Gaudieri, Silvana; Thio, Chloe; Bochud, Pierre-Yves (2009). Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics, 10(11), pp. 1819-37. London: Future Medicine 10.2217/PGS.09.121
Martin, Annalise; Nolan, David; Almeida, Coral-Ann; Rauch, Andri; Mallal, Simon (2006). Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics, 7(1), pp. 15-23. London: Future Medicine 10.2217/14622416.7.1.15
